Meeting Patient Needs on a Global Scale
Janssen is committed to meeting patient needs in established and new markets around the world. With the expansion of our global commercial portfolio, we are introducing new therapies for people living with neuropsychiatric, neurological, neurodegenerative, and autoantibody-driven diseases.
We have a global, integrated team of diverse and world-renowned talent and partners who are required to bring therapeutic options to patients who need them most.
Our capabilities include global development programs, world-class manufacturing of biologics and small molecules, and strong commercialization entities that market our products in more than 175 countries. We are part of the most broadly based healthcare company in the world, yet our decentralized structure assures that we remain focused on the markets in every therapeutic and geographic area that we serve.
As such, we recognize the importance of ensuring our medicines are globally available. Our market-access strategy is focused on delivering clinical and payor value through evidence generation, innovative payor partnerships, and private market options.
Beyond this, we actively pursue licensing, acquisitions, academic partnerships, and public-private partnership opportunities to advance knowledge, education, and innovation in both established and emerging markets.